Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Developments in the treatment of myeloma

Mahmoud Gaballa • 5 Feb 2021
TCT 2021
Multiple Myeloma Daratumumab

Mahmoud Gaballa, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explores future developments in the treatment and management of patients with multiple myeloma, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Mahmoud Gaballa

2:35
Latest advances in CAR-T for multiple myeloma: cilta-cel & new CAR-T platforms
Mahmoud Gaballa • 22 Apr 2022
1:51
KRD vs VRD in high-risk multiple myeloma prior to autoHSCT
Mahmoud Gaballa • 22 Apr 2022
1:21
VRD induction, Mel200-conditioned autoHSCT and lenalidomide maintenance in multiple myeloma
Mahmoud Gaballa • 22 Apr 2022
4:55
Long-term outcomes of VRD, auto-HCT with Mel200 conditioning & lenalidomide maintenance in MM
Mahmoud Gaballa • 5 Feb 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals